U.S. Physical Therapy stock
USPHNYSEU.S. Physical Therapy, Inc., HealthcareISIN US90337L1089
55Score 55 out of 100, Neutral
Price and trend
83 / 100
Price history
+36% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 28% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 70).
The price is 1.5% below its 52-week high. Largest decline in 20 years: 67% (November 2019 to March 2020).
Chart figures for advanced users
- SMA 50$85.83
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$77.17
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)70
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$59.00
- The lowest closing price of the last twelve months.
- Resistance$100.10
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- U.S. Physical Therapy, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $1.47B, is number 37 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $780.99M (up 16.3% year on year) and earnings of $15.06M (down 43.1%).
- For fiscal 2026, analysts expect on average revenue of $849.18M (up 8.7%) and adjusted earnings per share of $2.85 (up 8.8%).
Show more
- MEQIRI Score 55 out of 100 (Neutral): rank 339 of 714 in Healthcare, median 53.
- Our model puts fair value at $45.16, with the price 122% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 15 years.
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 78
Weaknesses
- Above fair valuePrice 122% above the fair value of $45.16.Valuation 20
- Loss-makingLoss of $2.23M over the last 12 months.
- Earnings per share fallingDown 19.1% a year since 2020.Growth 39
Its standout strengths are momentum and technical analysis, while profitability and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- price near its 52-week high
- stable momentum
- solid fundamentals
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $34.74 and expensive above $64.51 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $38.49, at 7.8% it would be $55.10.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 26.7% on the twelve months before. Revenue has grown solidly since 2006, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 20%, operating 10%, net 2%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported $0.80 (expected $0.76)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.85−1.7%
- Revenue
- $849.18M+0.2%
- Earnings per share
- $3.37−1.6%
- Revenue
- $913.6M+0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +3.0%2026 adjusted EBITDA guidance of $102 million to $106 million reaffirmed.
“Taking into account the year-to-date 2026 results and the expected increasing benefit of hospital affiliations in the back half of the year, we are reaffirming our full year 2026 adjusted EBITDA guidance of $102 million to $106 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $49,251 in total.
- Minan Peter FrancisPurchase
11 Sept 2026, Board
- Shares
- 5.27
- Price
- $79.00
- Value
- $416
- Minan Peter FrancisPurchase
12 Jun 2026, Board
- Shares
- 0.87
- Price
- $66.50
- Value
- $58
- Minan Peter FrancisPurchase
9 Jun 2026, Board
- Shares
- 288
- Price
- $61.50
- Value
- $17,712
Show 1 more
- Minan Peter FrancisPurchase
8 Jun 2026, Board
- Shares
- 492
- Price
- $63.14
- Value
- $31,065
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at U.S. Physical Therapy
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 55
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Healthcare Services GroupHCSG $1.7B70
- Sonida Senior LivingSNDA $1.67B32
- AmbeaAMBEA.ST $1.64B70
- Astrana HealthASTH $1.63B54
- AMN Healthcare ServicesAMN $1.47B65
- Aevis VictoriaAEVS.SW $1.45B34
- ClarianeCLARI.PA $1.37B39
- Nutex HealthNUTX $1.3B74
ETFs that hold U.S. Physical Therapy
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.07% | 0.30% | €2.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.07% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.22B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.05% | 0.30% | €2.17B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.02% | 0.30% | €944.34M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.19B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.